AZN Astrazeneca PLC
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Company profile
Ticker
AZN, AZNCF
Exchange
Website
CEO
Pascal Soriot
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ZENECA GROUP PLC
SEC CIK
Corporate docs
AZN stock data
()
Calendar
3 Mar 20
26 Nov 20
31 Dec 20
News
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 19 Dec 19 | Astrazeneca | Common Stock | Buy | Aquire P | No | 0 | 12,946,900 | 0 | 12,946,900 |
| 7 Oct 19 | Astrazeneca | Common Stock | Buy | Aquire P | No | 19 | 425,000 | 8.08M | 14,650,334 |
| 7 Oct 19 | Astrazeneca | Common Stock | Conversion | Aquire C | No | 0 | 14,225,324 | 0 | 14,225,334 |
| 7 Oct 19 | Astrazeneca | Series A-1 Preferred Stock Common Stock | Conversion | Dispose C | No | 0 | 14,225,324 | 0 | 0 |
Institutional ownership Q2 2020
0.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2 |
| Opened positions | 1 |
| Closed positions | 1 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 7K |
| Total shares | 66 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Captrust Financial Advisors | 66 | $7K |
| IFP Advisors | 0 | $0 |
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
6th grade Avg
|
|
New words:
accuracy, alter, antagonist, Asia, atenolol, belong, Brexit, Breztri, Building, built, chemoradiation, chlorthalidone, chronic, CLL, communicated, communicating, communication, comparison, complex, constipation, critical, CVOT, DBTCA, dealing, depend, Description, Deutsche, device, dipeptidyl, directed, DOJ, Duaklir, earlier, effort, erosion, ESPC, fiscal, forecasted, formulary, headroom, heavily, highly, historical, hospital, hydrochlorothiazide, identification, Inderal, inflation, inquiry, intervene, Israel, Italy, judgement, judgment, jurisdiction, leukaemia, likelihood, lisinopril, long, lymphocytic, mandated, manner, Medicare, method, methodology, monitoring, mortality, naloxegol, NHSA, OIC, outcome, Pacific, PAMORA, peak, peripherally, point, Prasco, processed, procurement, projected, propranolol, protein, Purpose, quantified, range, realised, reappointment, recognise, recognised, reconciling, recoverability, recoverable, RedHill, regaining, relied, retail, retrospective, role, segment, sensitive, sensitivity, skill, SLL, slower, small, software, sought, specialised, successor, tam, technical, Tenoretic, Tenormin, transport, trust, turn, unauthorised, uncontrolled, unexpected, unlawful, unsettled, variable, whistleblower, Zestoretic, Zestril
Removed:
Achieve, acquired, addressed, adjusted, adjustment, agree, alliance, Almirall, amortisation, amounting, applied, approve, arose, arrive, asset, auditing, balance, BMS, bond, broadly, calculated, chemotherapy, CHMP, column, comparative, copy, cost, credit, daily, decision, decrease, deferred, depreciation, detailed, disagreement, disclaimer, dismissed, disposal, divided, dollar, element, employer, ending, EPS, euro, Excluded, Externalisation, fair, finance, foregoing, formal, furnish, hedging, herewith, HQ, invest, investment, joint, June, KPMG, low, lower, manufacturing, margin, MedImmune, modified, olaparib, option, organisation, owing, participated, principally, proceeding, prohibited, propose, proposed, PwC, receivable, reduced, remeasurement, removing, repaid, reportable, requested, resolved, Rest, restructuring, retirement, rotation, royalty, satisfaction, scientific, scope, serve, spend, stating, transfer, trial, UKLA, unauthorized, unsuccessful, unwind, venture, York, ZS
Financial reports
20-F
2019 FY
Annual report (foreign)
3 Mar 20
20-F
2018 FY
Annual report (foreign)
5 Mar 19
20-F
2017 FY
Annual report (foreign)
6 Mar 18
20-F
2016 FY
Annual report (foreign)
7 Mar 17
20-F
2015 FY
Annual report (foreign)
8 Mar 16
20-F
2014 FY
Annual report (foreign)
10 Mar 15
20-F
2013 FY
Annual report (foreign)
20 Mar 14
20-F
2012 FY
Annual report (foreign)
25 Mar 13
20-F/A
2011 FY
Annual report (foreign) (amended)
21 Sep 12
20-F
2011 FY
Annual report (foreign)
28 Mar 12
Current reports
6-K
AZD1222 Vaccine Effective Against COVID-19
23 Nov 20
6-K
Imfinzi New Dosing Approved In the Us
20 Nov 20
6-K
Tezepelumab Phase III Trial Met Primary Endpoint
10 Nov 20
6-K
Calquence Approved In the Eu for CLL
9 Nov 20
6-K
Brilinta Approved In the Us In Stroke
6 Nov 20
6-K
Azn: Year-to-date and Q3 2020 Results
5 Nov 20
6-K
Forxiga Approved In the Eu for Heart Failure
5 Nov 20
6-K
Lynparza Approved In the Eu As 1ST-LINE Maintenance Treatment with Bevacizumab for Hrd-positive Advanced Ovarian Cancer
5 Nov 20
6-K
Lynparzaapproved In the Eu for the Treatment of Brca- Mutated Metastatic Castration-resistant Prostate Cancer
5 Nov 20
6-K
Total Voting Rights
2 Nov 20
Registration and prospectus
25-NSE
Exchange delisting
13 Nov 20
8-A12B
Registration of securities on exchange
24 Sep 20
25
Voluntary exchange delisting
24 Sep 20
8-A12B
Registration of securities on exchange
6 Aug 20
424B2
Prospectus for primary offering
5 Aug 20
FWP
Free writing prospectus
4 Aug 20
S-8
Registration of securities for employees
3 Aug 20
FWP
Free writing prospectus
3 Aug 20
424B2
Prospectus for primary offering
3 Aug 20
F-6
Registration for ADRs (foreign)
22 Jan 20
Proxies
No filings
Other
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
3 Mar 20
EFFECT
Notice of effectiveness
7 Feb 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 18
CERTNYS
Certification of approval for NYSE listing
14 Jun 17
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
8 Mar 17
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
8 Mar 16
CERTNYS
Certification of approval for NYSE listing
18 Nov 15
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
10 Mar 15
EFFECT
Notice of effectiveness
5 Dec 14
Ownership
4
Change in insider ownership
7 Feb 20
3
Initial statement of insider ownership
7 Feb 20
SC 13D
Beneficial ownership report
7 Feb 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
SC 13G
Viela Bio, Inc.
30 Jan 20
SC 13G/A
Astrazeneca PLC
27 Jan 20
SC 13D
Innate Pharma SA
25 Oct 19
4
Change in insider ownership
9 Oct 19
3/A
Initial statement of insider ownership (amended)
9 Oct 19
3
Initial statement of insider ownership
3 Oct 19